Riverview Capital Advisers LLC Decreases Position in Tempus AI, Inc. $TEM

Riverview Capital Advisers LLC decreased its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 21.5% in the third quarter, Holdings Channel reports. The firm owned 36,441 shares of the company’s stock after selling 10,000 shares during the period. Riverview Capital Advisers LLC’s holdings in Tempus AI were worth $2,941,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Renaissance Capital LLC raised its stake in Tempus AI by 26.9% in the third quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock valued at $6,793,000 after buying an additional 17,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Tempus AI by 1,459.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock valued at $8,174,000 after acquiring an additional 94,783 shares in the last quarter. Hussman Strategic Advisors Inc. purchased a new position in shares of Tempus AI in the 3rd quarter valued at approximately $1,695,000. Vanguard Group Inc. boosted its stake in Tempus AI by 22.1% in the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after purchasing an additional 1,706,837 shares in the last quarter. Finally, Krane Funds Advisors LLC boosted its stake in Tempus AI by 218.2% in the 3rd quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock worth $2,427,000 after purchasing an additional 19,358 shares in the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Trading Down 3.9%

NASDAQ TEM opened at $53.25 on Monday. Tempus AI, Inc. has a 1 year low of $36.22 and a 1 year high of $104.32. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The company has a market capitalization of $9.47 billion, a PE ratio of -37.77 and a beta of 5.29. The company has a fifty day moving average of $61.34 and a 200 day moving average of $73.35.

Insiders Place Their Bets

In other news, CEO Ryan Fukushima sold 9,592 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $566,407.60. Following the sale, the chief executive officer owned 694,354 shares in the company, valued at $41,001,603.70. This represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Andrew Polovin sold 10,949 shares of the firm’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $60.31, for a total value of $660,334.19. Following the sale, the executive vice president directly owned 126,918 shares in the company, valued at approximately $7,654,424.58. This trade represents a 7.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 590,109 shares of company stock worth $37,056,566. 26.27% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Robert W. Baird began coverage on shares of Tempus AI in a report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price objective on the stock. Needham & Company LLC cut their target price on Tempus AI from $100.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Morgan Stanley lifted their price target on Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Finally, Wall Street Zen downgraded Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $79.31.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.